Semax vs Selank: identities, research models and evidence limits
Semax and Selank are different seven-residue peptides with distinct parent sequences. Their literature includes animal experiments and human studies with different endpoints. A meaningful comparison preserves the exact molecule, model and measurement; it cannot turn gene-expression or brain-imaging differences into a ranking of therapeutic benefit.
Start with the two molecular identities
Semax is Met–Glu–His–Phe–Pro–Gly–Pro, abbreviated MEHFPGP. Its design joins an ACTH-derived four-residue sequence to Pro–Gly–Pro. Selank is Thr–Lys–Pro–Arg–Pro–Gly–Pro, abbreviated TKPRPGP, combining the tuftsin sequence with the same three-residue extension.
The shared ending does not make them interchangeable. Descriptions such as “ACTH-related” or “tuftsin analogue” identify their design background; they do not establish that either reproduces every function of its parent molecule. Modified derivatives also need their own identity and evidence rather than inheriting findings from a familiar name.
What the selected Semax experiments actually measured
Shadrina et al. (2010; published online 2009) reported a rat study that examined NGF and BDNF gene expression in the hippocampus, frontal cortex and retina at several time points. The indexed abstract describes different directions of change depending on tissue and timing. Reducing this to “Semax increases BDNF” removes information needed to understand the result.
Medvedeva and colleagues used a different setting in 2014: rats with experimentally induced focal cerebral ischaemia. They compared cortical gene expression after Semax with the ischaemia control group and reported changes involving immune and vascular processes. This is evidence about transcription in an injury model, not a test of improved everyday concentration.
What the Selank neurotransmission study adds
Volkova and colleagues assessed 84 neurotransmission-related genes in rat frontal cortex after Selank or GABA exposure. Some early expression changes were correlated between the conditions, while other responses differed.
This supports investigation of GABA-related signalling. It does not, by itself, demonstrate that Selank binds a particular receptor site or acts identically to an established medicine. An expression profile is a downstream observation; proving a direct molecular target requires evidence that specifically tests that target.
Human research exists, but its reporting matters
A 2008 clinical report compared Selank in 30 patients with medazepam in 32 patients with generalised anxiety disorder or neurasthenia. Its English abstract describes symptom scales and serum enkephalin measurements. It does not provide enough detail to independently assess all aspects of allocation, masking, missing data or adverse-event collection.
Only that indexed abstract was assessed for this guide. The study should therefore be acknowledged without treating a brief reported comparison as proof of equivalence, established long-term safety or relevance to healthy people.
The direct Semax–Selank comparison was an imaging study
Panikratova and colleagues studied 52 healthy participants in 2020. Separate groups received Semax, Selank or placebo, and resting-state fMRI assessed brain connectivity before exposure and at two short-term follow-ups. The abstract reports group- and condition-related differences involving right-amygdala connectivity.
This is a human mechanistic comparison. It was not a study of taking both compounds together, and its imaging endpoint does not establish symptom relief, durable memory improvement or which peptide is “better.” The abstract does not establish every design safeguard, so this guide does not add unreported claims of blinding or randomisation.
Keep each study in its own evidence category
This selection illustrates different research questions rather than attempting a systematic review. A result becomes misleading when its original population or endpoint disappears from the summary.
| Study | Model and measurement | Interpretive boundary |
|---|---|---|
| Semax: Shadrina et al. (2010; published online 2009) | Rat tissues; NGF and BDNF expression over time | A molecular change is not a measured cognitive outcome. |
| Semax, 2014 | Rat ischaemia; cortical transcriptome | Injury-model findings need their disease context. |
| Selank, 2016 | Rat cortex; neurotransmission-related genes | Correlation does not prove a direct binding site. |
| Selank, 2008 | Patient comparator study; symptom and serum measures | Abstract-level appraisal leaves methodological gaps. |
| Semax and Selank, 2020 | Healthy volunteers; short-term fMRI connectivity | An imaging difference does not rank clinical benefit. |
A practical way to read the next paper
Begin with the material: exact sequence, modifications and formulation. Then record the species or participant population, comparator, prespecified endpoint and observation period. Keep an exploratory laboratory measurement separate from a patient outcome.
When only an abstract is available, say so. Do not invent missing methods, interpret silence about adverse events as an absence of risk, or count several papers from overlapping investigators as independent replication without checking. For comparisons, ask whether both compounds were tested under the same conditions and whether the endpoint actually answers the proposed question.
Separate literature identity from catalogue documentation
For FSD materials, check the product specification and original analytical report for the selected material. A compound name in a paper does not connect that experiment to a particular catalogue batch. Identity, measured purity, quantity and stock-lot traceability remain separate documentation questions.
FSD materials are supplied for laboratory research, not human or veterinary administration. These articles explain evidence and documentation; they do not establish clinical-grade equivalence or provide instructions for personal use.
Common questions
Are Semax and Selank the same peptide?
No. They share a Pro–Gly–Pro ending but have different preceding sequences and different molecular identities.
Does “human study” always mean proven clinical benefit?
No. Human research can examine an imaging or laboratory endpoint. Read the actual outcome, duration and population before drawing a clinical conclusion.
Does this comparison recommend one for a particular condition?
No. It explains how to read different types of evidence. The selected studies do not establish a general therapeutic ranking between the two peptides.
Sources & scope
These references explain analytical and research principles. They do not certify FSD BIO LABS or provide evidence about a particular FSD batch.
- Semax and the rat-brain transcriptome after focal ischaemia (2014) — Medvedeva et al. · BMC Genomics
Primary rat study, full text consulted. Supports Semax sequence and immune- and vascular-related gene-expression findings after permanent arterial occlusion. This experiment did not measure treatment outcomes in people. - Shadrina et al. (2010; published online 2009): Semax, NGF and BDNF expression in rat tissues — Journal of Molecular Neuroscience · indexed primary abstract
Primary rat experiment; description limited to the indexed abstract. Supports differing neurotrophin gene-expression responses across sampled tissues and times, not a uniform increase or demonstrated human cognitive benefit. - Selank and genes involved in GABAergic neurotransmission (2016) — Volkova et al. · Frontiers in Pharmacology
Primary rat study, full text consulted. Supports Selank identity and a neurotransmission-related expression comparison with GABA. Similar expression patterns do not independently establish a direct receptor-binding mechanism. - Selank and medazepam in anxiety disorders and neurasthenia (2008) — Zozulia et al. · Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova
Primary clinical report involving 62 patients; only the English indexed abstract was assessed. Supports the stated patient groups, comparator and assessments. Incomplete abstract reporting limits appraisal of methods and safety. - Functional Connectomic Approach to Studying Selank and Semax Effects (2020) — Panikratova et al. · Doklady Biological Sciences
Primary human imaging study; summary limited to the indexed abstract. Separate Semax, Selank and placebo groups were studied among 52 healthy participants. Connectivity findings are not evidence of clinical superiority or combination efficacy.